Important Information for Rocket Pharmaceuticals Investors
The Gross Law Firm has an important notification for investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). There has been a pending class action lawsuit, which is significant for shareholders who acquired shares during the specified periods. This provides an opportunity for shareholders to engage in the legal process concerning the company's actions.
Eligible Shareholders and Lead Plaintiff Appointment
Shareholders who purchased RCKT shares are encouraged to reach out to the Gross Law Firm regarding the potential for appointment as the lead plaintiff in this case. It’s important to note that being appointed as the lead plaintiff is not a requirement to benefit from any recovery that may arise from the lawsuit.
Class Period Details
The class period for this lawsuit encompasses transactions from February 27, 2025, to May 26, 2025. These dates are critical for shareholders looking to establish their eligibility. Contacting the law firm promptly can maximize your potential participation in this class action.
Background of the Allegations
According to the allegations, the defendants provided overly optimistic statements about Rocket's RP-A501 drug while failing to disclose critical and adverse facts. This included information about Serious Adverse Events, including the unfortunate deaths of study participants, which the company did not make known to shareholders. The lawsuit contends that misleading statements caused investors to purchase shares at inflated prices.
Key Events and Their Impact
On May 27, 2025, Rocket Pharmaceuticals disclosed that the FDA had placed a clinical hold on the Phase 2 study of RP-A501 due to serious safety issues. Following this revelation, the company's stock plummeted significantly, reducing from $6.27 to $2.33 in a single day—a staggering drop of approximately 37%. Such market reactions highlight the importance of transparency and accurate communication from companies.
Urgent Deadline for Shareholders
Shareholders must act without delay. The deadline for registering as part of the class action is August 11, 2025. It is crucial to register your participation to ensure your rights are protected throughout the legal proceedings.
Steps for Shareholders Moving Forward
Upon registering, you will be equipped with portfolio monitoring tools to keep you informed during the case's lifecycle. This monitoring is provided without any cost or commitments on your part. The Gross Law Firm is dedicated to keeping shareholders updated with relevant information regarding their involvement and the overall status of the lawsuit.
Why Choose The Gross Law Firm?
The Gross Law Firm is recognized nationally for its commitment to safeguarding investor rights. They focus on holding companies accountable for fraudulent or misleading practices. Their mission is to ensure responsible business practices and support investors who have suffered financial losses due to deceitful company actions.
Contact Information for Assistance
If you are a shareholder seeking additional information or interested in the class action, reach out to The Gross Law Firm at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for the lawsuit?
The class period runs from February 27, 2025, to May 26, 2025.
What should I do if I purchased RCKT shares?
If you purchased shares during the class period, consider contacting The Gross Law Firm for more information about your rights and potential participation in the lawsuit.
What are the allegations against Rocket Pharmaceuticals?
The lawsuit alleges that the company misled investors regarding the safety of RP-A501 and failed to disclose significant adverse events during its clinical trials.
How can I get updates on the case?
Once registered, you will receive regular updates on the case's status and any relevant developments.
Is there a cost to participate in the class action?
No, participating in the class action has no associated costs or obligations for shareholders.
